首页> 外国专利> Delivery of a drug via subconjunctival or periocular delivery of a prodrug in a polymeric microparticle

Delivery of a drug via subconjunctival or periocular delivery of a prodrug in a polymeric microparticle

机译:通过结膜下或前体在聚合物微粒中眼周递送药物

摘要

Disclosed is a use of an ester prodrug of an active drug useful in treating a disease or condition affecting the back of the eye in the manufacture of a medicament for the treatment or prevention of retinitis pigmentosa, proliferative vitreal retinopathy, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal detachment, retinal tear, uveitus, or cytomegalovirus retinitis, wherein the medicament is formulated for sustained-delivery of the active drug to a posterior part of an eye of a mammal by subconjunctival or periocular administration, wherein the prodrug is contained in a polymeric microparticle system designed to enhance the sustained-delivery of said ester prodrug of an active drug, wherein said polymeric microparticle system is a poly(lactide co-glycolide) microsphere suspension, and wherein the ester prodrug of the active drug is not tazarotene or another retinoid. Also disclosed is a composition comprising the microspheres and a method for making microspheres.
机译:公开了活性药物的酯前药在制备用于治疗或预防色素性视网膜炎,增生性玻璃体视网膜病,年龄相关性黄斑变性的药物的制造中用于治疗影响眼后部的疾病或病症的用途,糖尿病性视网膜病,糖尿病性黄斑水肿,视网膜脱离,视网膜撕裂,葡萄膜或巨细胞病毒性视网膜炎,其中所述药物被配制用于通过结膜下或眼周施用将活性药物持续递送至哺乳动物的眼睛的后部,其中前药包含在设计用于增强活性药物的所述酯前药的持续递送的聚合物微粒系统中,其中所述聚合物微粒系统是聚丙交酯乙交酯微球悬浮液,并且其中活性药物的酯前药不是他扎罗汀或其他类维生素A。还公开了包含微球的组合物和制备微球的方法。

著录项

  • 公开/公告号NZ582376A

    专利类型

  • 公开/公告日2012-02-24

    原文格式PDF

  • 申请/专利权人 ALLERGAN INC.;

    申请/专利号NZ20040582376

  • 发明设计人 HUGHES PATRICK M;OLEJNIK OREST;

    申请日2004-07-07

  • 分类号A61K47/48;A61K9;A61K9/16;A61K31/203;A61K31/557;

  • 国家 NZ

  • 入库时间 2022-08-21 17:23:27

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号